November 2012

Cutting edge Phase 1 study is initiated in cancer patients

2 November 2012

We are excited to announce the commencement of a cutting edge Phase 1 study  deploying a live genetically modified virus to treat cancer patients with advanced solid tumours. In addition to trials using oncolytic viruses we also work on other studies translating innovative anti-cancer strategies into clinical trials including (a) novel therapies in which cancer genes are switched off (transcriptional targeting) with the aim of causing cancer-specific cell death, and b) the study of certain gene products as potential tumour associated antigens which can be targeted by cancer vaccines.